Hematopoietic stem cell transplantations have become a very successful therapeutic approach to treat otherwise life-threatening blood disorders. It is thought that stem cell transplantation may also become a feasible treatment option for many non-blood-related diseases. So far, however, the limited availability of human leukocyte antigen-matched donors has hindered development of some cell replacement therapies. The Nobel-prize rewarded finding that pluripotency can be induced in somatic cells via expression of a few transcription factors has led to a revolution in stem cell biology. The possibility to change the fate of somatic cells by expressing key transcription factors has been used not only to generate pluripotent stem cells, but also for directly converting somatic cells into fully differentiated cells of another lineage or more committed progenitor cells. These approaches offer the prospect of generating cell types with a specific genotype de novo, which would circumvent the problems associated with allogeneic cell transplantations. This technology has generated a plethora of new disease-specific research efforts, from studying disease pathogenesis to therapeutic interventions. Here we will discuss the opportunities in this booming field of cell biology and summarize how the scientists in the Netherlands have joined efforts in one area to exploit the new technology.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 1233151.
2.
AmabileG., et al. (2013). In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood, 121, 1255–1264.
3.
ArakiR., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 494, 100–104.
4.
BarberA.C., et al. (2013). Repair of the degenerate retina by photoreceptor transplantation. Proc. Natl. Acad. Sci. USA, 110, 354–359.
5.
Ben-DavidU., et al. (2013). Selective elimination of human pluripotent stem cells by an oleate synthesis inhibitor discovered in a high-throughput screen. Cell Stem Cell, 12, 167–179.
6.
BiascoL., et al. (2012). Retroviral integrations in gene therapy trials. Mol. Ther., 20, 709–716.
ChenG., et al. (2011). Chemically defined conditions for human iPSC derivation and culture. Nat. Methods, 8, 424–429.
9.
ChongJ.J., et al. (2014). Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature, 510, 273–277.
10.
CortiS., et al. (2010). Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice. Brain, 133, 465–481.
11.
DambrotC., et al. (2013). Polycistronic lentivirus induced pluripotent stem cells from skin biopsies after long term storage, blood outgrowth endothelial cells and cells from milk teeth. Differentiation, 85, 101–109.
12.
DarabiR., et al. (2012). Human ES- and iPS-derived myogenic progenitors restore Dystrophin and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell, 10, 610–619.
13.
DeKelverR.C., et al. (2010). Functional genomics, proteomics, and regulatory DNA analysis in isogenic settings using zinc finger nuclease-driven transgenesis into a safe harbor locus in the human genome. Genome Res., 20, 1133–1142.
14.
De KoningJ., et al. (1969). Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet, 1, 1223–1227.
15.
Faulkner-JonesA., et al. (2013). Development of a valve-based cell printer for the formation of human embryonic stem cell spheroid aggregates. Biofabrication, 5, 015013.
16.
FilaretoA., et al. (2013). An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat. Commun., 4, 1549.
17.
FuJ.D., et al. (2013). Direct reprogramming of human fibroblasts toward a cardiomyocyte-like state. Stem Cell Rep., 1, 235–247.
18.
GajT., et al. (2013). ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol., 31, 397–405.
19.
GattiR.A., et al. (1968). Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet, 2, 1366–1369.
20.
GoreA., et al. (2011). Somatic coding mutations in human induced pluripotent stem cells. Nature, 471, 63–67.
21.
GuhaP., et al. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 12, 407–412.
22.
GuptaN., et al. (2012). Neural stem cell engraftment and myelination in the human brain. Sci. Transl. Med., 4, 155ra137.
23.
HorwitzE.M., et al. (1999). Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med., 5, 309–313.
24.
HuangJ.K., and FranklinR.J. (2012). Current status of myelin replacement therapies in multiple sclerosis. Progress Brain Res., 201, 219–231.
25.
HusseinS.M., et al. (2011). Copy number variation and selection during reprogramming to pluripotency. Nature, 471, 58–62.
26.
KazukiY., et al. (2010). Complete genetic correction of iPS cells from Duchenne muscular dystrophy. Mol. Ther., 18, 386–393.
27.
KeirsteadH.S., et al. (2005). Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J. Neurosci., 25, 4694–4705.
28.
KirkK., et al. (2014). Human embryonic stem cell derived islet progenitors mature inside an encapsulation device without evidence of increased biomass or cell escape. Stem Cell Res., 12, 807–814.
29.
KobayashiT., et al. (2010). Generation of rat pancreas in mouse by interspecific blastocyst injection of pluripotent stem cells. Cell, 142, 787–799.
30.
KolliS., et al. (2010). Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency. Stem Cells, 28, 597–610.
31.
KriksS., et al. (2011). Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature, 480, 547–551.
32.
LandM.H., et al. (2007). Long-term results of bone marrow transplantation in complete DiGeorge syndrome. J. Allergy Clin. Immunol., 120, 908–915.
33.
LaurentL.C., et al. (2011). Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture. Cell Stem Cell, 8, 106–118.
34.
LindvallO., and BjorklundA. (2004). Cell therapy in Parkinson's disease. NeuroRx, 1, 382–393.
35.
LoughD.M., et al. (2014). Transplantation of the LGR6+ epithelial stem cell into full-thickness cutaneous wounds results in enhanced healing, nascent hair follicle development, and augmentation of angiogenic analytes. Plastic Reconstr. Surg., 133, 579–590.
36.
MarkertM.L., et al. (1999). Transplantation of thymus tissue in complete DiGeorge syndrome. N. Engl. J. Med.icine, 341, 1180–1189.
37.
MavilioF., et al. (2006). Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med., 12, 1397–1402.
38.
MikiK., et al. (2013). Making steady progress on direct cardiac reprogramming toward clinical application. Circ. Res., 113, 13–15.
39.
NamY.J., et al. (2013). Reprogramming of human fibroblasts toward a cardiac fate. Proc. Natl. Acad. Sci. USA, 110, 5588–5593.
40.
NishimuraK., et al. (2012). Fates of murine pluripotent stem cell-derived neural progenitors following transplantation into mouse cochleae. Cell Transplant., 21, 763–771.
41.
NorrmanK., et al. (2010). Quantitative comparison of constitutive promoters in human ES cells. PloS One, 5, e12413.
42.
OkitaK., et al. (2011). A more efficient method to generate integration-free human iPS cells. Nat. Methods, 8, 409–412.
43.
PietrosiG., et al. (2014). Phase I-II matched case-control study of human fetal liver cell transplantation for treatment of chronic liver disease. Cell Transplant.
44.
PrasadV.K., and KurtzbergJ. (2008). Emerging trends in transplantation of inherited metabolic diseases. Bone Marrow Transplant., 41, 99–108.
45.
QiangL., et al. (2011). Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. Cell, 146, 359–371.
46.
RezaniaA., et al. (2012). Maturation of human embryonic stem cell-derived pancreatic progenitors into functional islets capable of treating pre-existing diabetes in mice. Diabetes, 61, 2016–2029.
47.
RiddellJ., et al. (2014). Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell, 157, 549–564.
48.
RobinsM.M., and NoyesW.D. (1961). Aplastic anemia treated with bone-marrow transfusiuon from an identical twin. N. Engl. J. Med., 265, 974–979.
49.
RoesslerR., et al. (2014). Detailed analysis of the genetic and epigenetic signatures of iPSC-derived mesodiencephalic dopaminergic neurons. Stem Cell Rep., 2, 520–533.
50.
RossP.J., et al. (2010). Human-induced pluripotent stem cells produced under xeno-free conditions. Stem Cells Dev., 19, 1221–1229.
51.
SatoT., and CleversH. (2013). Growing self-organizing mini-guts from a single intestinal stem cell: mechanism and applications. Science, 340, 1190–1194.
52.
SchwartzS.D., et al. (2012). Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet.
53.
SmithA.J., et al. (2012). Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl. Med., 1, 709–718.
54.
SunX., et al. (2013). Directed differentiation of human embryonic stem cells into thymic epithelial progenitor-like cells reconstitutes the thymic microenvironment in vivo. Cell Stem Cell, 13, 230–236.
55.
SuzukiN., et al. (2013). Generation of engraftable hematopoietic stem cells from induced pluripotent stem cells by way of teratoma formation. Mol. Ther., 21, 1424–1431.
56.
TaianiJ.T., et al. (2014). Embryonic stem cell therapy improves bone quality in a model of impaired fracture healing in the mouse; tracked temporally using in vivo micro-CT. Bone, 64, 263–272.
57.
TakahashiK., et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 131, 861–872.
58.
TakebeT., et al. (2013). Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature, 499, 481–484.
59.
TaylorC.J., et al. (2005). Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet, 366, 2019–2025.
60.
TedescoF.S., et al. (2012). Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci. Transl. Med., 4, 140ra89.
61.
TengY.D., et al. (2012). Multimodal actions of neural stem cells in a mouse model of ALS: a meta-analysis. Sci. Transl. Med., 4, 165ra164.
62.
Transplantation survival in the Netherlands (2014). Available at www.transplantatiestichting.nl (accessed September2014).
63.
TyndallA. (2011). Successes and failures of stem cell transplantation in autoimmune diseases. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. Educ. Prog., 2011, 280–284.
64.
UchidaN., et al. (2012). Human neural stem cells induce functional myelination in mice with severe dysmyelination. Sci. Transl. Med., 4, 155ra136.
65.
van BekkumD.W., and MikkersH.M. (2012). Prospects and challenges of induced pluripotent stem cells as a source of hematopoietic stem cells. Ann. N.Y. Acad. Sci., 1266, 179–188.
66.
van RoodJ.J., et al. (1966). Current status of human leukocyte groups. Ann. N.Y. Acad. Sci., 129, 446–466.
67.
WagnerJ.E., et al. (2010). Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N. Engl. J. Med., 363, 629–639.
68.
WarmflashA., et al. (2014). A method to recapitulate early embryonic spatial patterning in human embryonic stem cells. Nat. Methods, 11, 847–854.
69.
WynnR. (2011). Stem cell transplantation in inherited metabolic disorders. Hematology/the Education Program of the American Society of Hematology. Am. Soc. Hematol. Educ. Prog., 2011, 285–291.
70.
XiaX., et al. (2007). Transgenes delivered by lentiviral vector are suppressed in human embryonic stem cells in a promoter-dependent manner. Stem Cells Dev., 16, 167–176.
71.
YooA.S., et al. (2011). MicroRNA-mediated conversion of human fibroblasts to neurons. Nature, 476, 228–231.
72.
ZhaoT., et al. (2011). Immunogenicity of induced pluripotent stem cells. Nature, 474, 212–215.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
